a hub for research, education & best practice
A network serving as a valuable resource for healthcare professionals working in the field of ILD, promoting research, education, and best practice in the diagnosis and management of these lung disorders.
The ILD-IN provides a supportive network for all members, encourages information sharing and promotes best practice and research collaboration.
The ILD-IN provides resources and materials and encourages members to develop knowledge and expertise in ILD care.
Through peer support and education, the ILD-IN aims to raise the standard and provision of ILD care.
Our purpose is to provide a supportive network for health professionals of all disciplines working in interstitial lung diseases. ILD-INs purpose is, to provide support, promote ILD specialty practice through education and professional development and to influence the policy of ILD care.
The Interstitial Lung Disease Interdisciplinary Network (ILD-IN) is a supportive and collaborative network for health professionals of all disciplines caring for people with interstitial lung disease (ILD).
The ILD-IN is keen to support the development of regional networks supporting healthcare professionals specialising in ILD locally.
New and established regional groups and their contacts are listed along with details of the next planned meeting. We would be pleased to list your network.
Take a look at our social wall to stay up-to-date on the latest events and news in the industry.
A great song by Andy Oliver to raise awareness of pulmonary fibrosis and raise money for @PFNI_NIRELAND #cureIPF @ipf_manchester @ild_inn @PFNI_NIRELAND @PilarRiveraOrt1 @LucillaPiccari @leticiakawano @KerriBerriKerri
Congratulations @CaritaBramhill on recognition of your work on unmet patient need in IPF. Best clinician poster @EU_IPFF #PFSUMMIT24 @ILFA_Ireland @tcddublin @ild_inn
Quantify yourself era: use home monitoring devices to offer good accessible care despite shortage of workforce and for monitoring between appointments to detect progression and gain access to treatments
Need to broaden patient inclusion criteria and consider how patient “feels, functions, survives.” Prof Marlies Wijsenbeek gives an overview of how we can improve diagnostic tools - use of #AI algorithms, novel technology.
Day 3 starts with @ActionPFsteve chairing an outstanding session on latest research in #pulmonaryfibrosis. @OrphaLung gives insights on new drugs in development & need for new drugs to demonstrate efficacy against current drugs so greater patient numbers are required #PFsummit24
Day 3 begins with an excellent talk from Vincent Cotton @EU_IPFF #PFSUMMIT24 ... Intro to changing face of clinical trial design in PPF @ild_inn @ers_ild
Prof Wim Wyuts @EU_IPFF speaks to Antigen avoidance & detailed exposure hx essential in HP before treating with corticosteroids. INBUILD demonstrated benefits of nintedanib effectiveness in fibrotic HP #IPFSUMMIT24 @ild_inn @ExeterMed
Dr Maria Molina Molina explains pathogenic gene variants in familial #pulmonaryfibrosis - surfactant gene abnormalities, telomere related gene mutations (accelerated lung fibrosis), MUC5B predisposition to developing lung fibrosis. Need standardised protocols for genetic tests.
@ActionPFwendy chairs the session on understanding pulmonary health and genetic factors. Clare Hodkinson shares her experiences of genetic testing. Benefits: earlier diagnosis, early lifestyle interventions. Barriers: long delays for PFTs/biopsy/results, lack of personalised tx